~Building an inclusive society~Santen and International Blind Sports Federation Forges Partnership through Blind Sports Posted Aug 11, 2020
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis Posted Jul 28, 2020
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program Posted Jul 22, 2020
Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review Posted Jul 7, 2020
Santen Introduces its New Corporate Brand Name Notation and Corporate Slogan Aiming to Grow on a Globally, Going beyond the Pharmaceutical Industry Posted Jul 7, 2020
Announcement of New Vision Aiming to Resolve Social Issues Related to the Eye Health of People around the World Posted Jul 7, 2020
Santen and Singapore's Health-tech Start-up, Plano Form a Strategic Alliance to Tackle the Global Burden of Myopia Posted Jun 30, 2020
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program Posted Jun 24, 2020
Santen and Orbis International Join Forces to Expand Access to Training for Eye Care Professionals through Telemedicine Platform Posted Jun 18, 2020
Providing Eye Care Information to Resolve Problems Caused by Excessive Screen Time Posted Jun 12, 2020
Bayer Yakuhin and Santen launch 'EYLEA Intravitreal Injection KIT 40mg/mL', pre-filled syringe of intravitreal VEGF Inhibitor EYLEA Posted Jun 5, 2020
Santen and jCyte Conclude an Exclusive Licensing Contract in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa Posted May 8, 2020
Santen, Together with Nonprofit Organization, Japan Blind Football Association, to Support People with Visual Impairments Facing the COVID-19 Pandemic Posted Apr 28, 2020
Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19) Posted Apr 1, 2020
Intravitreal VEGF Inhibitor EYLEA approved as a Treatment of Neovascular Glaucoma (NVG), its fifth indication Posted Mar 25, 2020
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration Posted Mar 10, 2020
Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020) Posted Mar 5, 2020
Beware of Suspicious E-mails and Messages on Social Media Claiming to be from Santen Pharmaceutical Co., Ltd. Posted Feb 27, 2020
Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices Posted Feb 4, 2020
Santen Pharmaceutical Selected as Title Sponsor of IBSA Blind Football World Grand Prix 2020! Posted Jan 23, 2020
Santen Pharmaceutical Signs Partnership Agreement with ITU Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology Posted Jan 10, 2020
